ScholarIQanswers from OpenAlex & ORCID
Marc S. Ernstoff
ResearcherPublications, citations & collaboration network
Marc S. Ernstoff is a researcher indexed in ScholarIQ from OpenAlex & ORCID.
How many works does Marc S. Ernstoff have?
ScholarIQindexed works
Marc S. Ernstoff has 568 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
How many citations does Marc S. Ernstoff have?
ScholarIQcitation count
Marc S. Ernstoff has 37,583 citations in the OpenAlex counts ScholarIQ stores.
What is the h-index of Marc S. Ernstoff?
ScholarIQh-index
Marc S. Ernstoff has an h-index of 81 in OpenAlex.
What is the i10-index of Marc S. Ernstoff?
ScholarIQi10-index
Marc S. Ernstoff has an i10-index of 252 in OpenAlex.
What is the ORCID of Marc S. Ernstoff?
ScholarIQorcid
The ORCID for Marc S. Ernstoff is on the source record.
What is the OpenAlex record for Marc S. Ernstoff?
ScholarIQopenalex
The OpenAlex for Marc S. Ernstoff is on the source record.
What are the most-cited papers on Marc S. Ernstoff?
ScholarIQmost cited works
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Julie R. Brahmer, Christina Lacchetti, Bryan J. Schneider, Michael B. Atkins, Kelly Brassil, Jeffrey M. Caterino, Ian Chau, Marc S. Ernstoff, Jennifer M. Gardner, Pamela Ginex, Sigrun Hallmeyer, Jennifer Holter Chakrabarty, Natasha B. Leighl, Jennifer S. Mammen, David F. McDermott, Aung Naing, Loretta J. Nastoupil, Tanyanika Phillips, Laura Porter, Igor Puzanov, Cristina Reichner, Bianca Santomasso, Carole Seigel, Alexander I. Spira, María E. Suarez‐Almazor, Yinghong Wang, Jeffrey S. Weber, Jedd D. Wolchok, John A. Thompson
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.
J M Kirkwood, M H Strawderman, Marc S. Ernstoff, Thomas J. Smith, E C Borden, Ronald H. Blum
High- and Low-Dose Interferon Alfa-2b in High-Risk Melanoma: First Analysis of Intergroup Trial E1690/S9111/C9190
John M. Kirkwood, Joseph G. Ibrahim, Vernon K. Sondak, Jon Richards, Lawrence E. Flaherty, Marc S. Ernstoff, Thomas J. Smith, Uma Rao, Mary Steele, Ronald H. Blum
Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events
Julie R. Brahmer, Hamzah Abu‐Sbeih, Paolo A. Ascierto, Jill Brufsky, Laura C. Cappelli, Frank B. Cortazar, David E. Gerber, Lamya Hamad, Eric Hansen, Douglas B. Johnson, Mario E. Lacouture, Gregory A. Masters, Jarushka Naidoo, Michele Nanni, Miguel‐Angel Perales, Igor Puzanov, Bianca Santomasso, Satish Shanbhag, Rajeev Sharma, Dimitra Skondra, Jeffrey A. Sosman, Michelle Turner, Marc S. Ernstoff
Management of Immunotherapy-Related Toxicities, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology
John A. Thompson, Bryan J. Schneider, Julie R. Brahmer, Stephanie Andrews, Philippe Armand, Shailender Bhatia, Lihua E. Budde, Luciano J. Costa, Marianne Davies, David Dunnington, Marc S. Ernstoff, Matthew J. Frigault, Brianna Hoffner, Christopher Hoimes, Mario E. Lacouture, Frederick L. Locke, Matthew A. Lunning, Nisha Mohindra, Jarushka Naidoo, Anthony J. Olszanski, Olalekan O. Oluwole, Sandip Pravin Patel, Sunil Reddy, Mabel Ryder, Bianca Santomasso, Scott Shofer, Jeffrey A. Sosman, Momen M. Wahidi, Yinghong Wang, Alyse Johnson-Chilla, Jillian L. Scavone